Search
Now showing items 1-3 of 3
Combined metabolic activators improve cognitive functions in Alzheimer's disease patients: A randomised, double-blinded, placebo-controlled phase-II trial
(BioMed Central Ltd, 2023)
Background: Alzheimer’s disease (AD) is associated with metabolic abnormalities linked to critical elements of neurodegeneration. We recently administered combined metabolic activators (CMA) to the AD rat model and observed ...
A structural and resting-state functional connectivity investigation of the pulvinar in elderly individuals and Alzheimer's disease patients
(John Wiley and Sons Inc, 2023)
In Alzheimer's disease (AD), structural and functional changes in the brain may give rise to disruption of specific cognitive functions. The aim of this study is to investigate the functional connectivity alterations in ...
Evaluating the clinical significance of diazepam binding inhibitor in alzheimer's disease: A comparison with inflammatory, oxidative, and neurodegenerative biomarkers
(Karger, 2023)
Introduction: Alzheimer's disease (AD) is one of the pathologies that the scientific world is still desperate for. The aim of this study was the investigation of diazepam binding inhibitor (DBI) as a prognostic factor for ...